Introduction: Hyperkalemia risk is increased in diabetes, particularly in patients with renal
angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs) or potassium-sparing diuretics. Conversely, other diuretics can increase hypokalemia risk. We assessed the effects of the sodium glucose co-transporter 2 (SGLT2) inhibitor dapagliflozin on serum potassium levels in a pooled analysis of clinical trials in patients with type 2 diabetes mellitus (T2DM).
Methods:
Fourteen randomized, placebo -controlled, double-blind T2DM studies were analyzed: pooled data from 13 studies of 
INTRODUCTION
Hyperkalemia, defined as a serum potassium level of greater than 5.5 mmol/L [1] , is a potentially life-threatening condition that causes increased cardiac depolarization and can lead to rapid electrocardiographic changes and an increased risk of arrhythmias [2] . Conversely, hypokalemia is defined as a serum potassium level of less than 3.5 mmol/L (mild) [3] or less than 2.5 mmol/L (severe) [4] and can lead to an increase in the risk of cardiac arrhythmias [3] . In addition to the risk associated with serum potassium outside the normal range (i.e., below or above normal levels), maintaining stable serum potassium values within physiological levels is important, as high serum potassium fluctuations are associated with increased all-cause and cardiovascular mortality [5] .
Patients with diabetes are at increased risk of hyperkalemia [6, 7] and diabetes is an independent risk factor for hyperkalemia [6, 8, 9] . In an outpatient population of patients with diabetes, the prevalence of hyperkalemia has been estimated at 4% [6] , whereas in a separate investigation in the general population, it has been estimated to be lower (0.3%) [10] .
Additionally, diabetes is associated with a high incidence of renal impairment, which in turn is an independent risk factor for hyperkalemia [9] .
Antihypertensive medications, which are frequently prescribed to these patients, can also increase serum potassium [11, 12] . For example, medications that reduce renal potassium excretion by inhibiting the renin-angiotensin-aldosterone system [such as angiotensin-converting enzyme (ACE)
inhibitors and angiotensin receptor blockers (ARBs)], and drugs that inhibit the epithelial sodium channel (known as potassium-sparing diuretics) are associated with a greater hyperkalemia risk [13, 14] . The combination of an ACE inhibitor or ARB and a potassium-sparing diuretic is likely to further increase potassium levels and has been shown to precipitate life-threatening hyperkalemia in patients with diabetes [15] [16] [17] . Conversely, other diuretics such as thiazides or loop diuretics are generally associated with an increased risk of hypokalemia [18] .
Older patients with diabetes have an increased susceptibility to hyperkalemia due to a number of factors, including an age-related decline in renal function and pharmaceutical side effects, such as those associated with ACE inhibitor or ARB treatment [19] .
Sodium glucose co-transporter 2 (SGLT2) inhibitors are a class of glucose-lowering drugs that improve glycemic control, produce favorable effects on body weight and blood pressure, and have a low associated risk of hypoglycemia [20] . Given the renal site of action of SGLT2 inhibitors and the mild diuresis associated with their mode of action [21] , there is potential concern about their effects on electrolyte balance, including potassium. Indeed, the SGLT2 inhibitor canagliflozin is associated with an increased risk of hyperkalemia [22] .
Dapagliflozin is a highly selective orally available SGLT2 inhibitor for the treatment of type 2 diabetes mellitus (T2DM) [23] . Phase IIb and III clinical studies have demonstrated that dapagliflozin has a favorable safety profile and is well tolerated as monotherapy [24] or in combination with other glucose-lowering agents [25] [26] [27] [28] [29] . Here we describe the results of a pooled analysis of dapagliflozin clinical trials in patients with T2DM that aimed to determine whether or not dapagliflozin 10 mg affected the risk of potassium imbalance.
METHODS

Patient Population
The analyzed population comprised short-term Data from a Phase II/III 52-week dedicated renal impairment study [30] , in which all patients had an eGFR at baseline of C30 to \60 mL/min/1.73 m 2 , were analyzed separately 
Outcomes Measures
Serum potassium levels were determined for each patient by central laboratory measurements at every study visit (at baseline, week 1 and week 4, then every 4 weeks up to week 24). Mean change in serum potassium levels from baseline were determined for dapagliflozin 10 mg versus placebo. This outcome was assessed in the pooled population (overall and in patients treated with ACE inhibitors or ARBs) up to week 24, and in the moderate renal impairment study over 52 weeks [30] .
The incidence of marked abnormalities of serum potassium C5.5 mmol/L and C6.0 mmol/ L were determined for dapagliflozin 10 mg compared with placebo. These cut-off points were selected as hyperkalemia is generally defined as a serum potassium level at or above the upper limit of normal (C5.5 mmol/L) [1] , whereas moderate hyperkalemia is generally defined as a serum potassium level of were assessed for dapagliflozin 10 mg versus placebo for the overall pooled population. The incidence of mild and severe hypokalemia (serum potassium B3.5 and B2.5 mmol/L, respectively) was also determined for dapagliflozin 10 mg versus placebo for the overall pooled population.
Analysis Methods
Presented mean changes from baseline and associated 95% confidence intervals (CI), which were calculated using the t-distribution method, were conducted with SAS/STAT Ò (SAS Institute Inc. Cary, NC, USA). For the analysis of the incidence of marked abnormalities of serum potassium, incidence rate ratios (IRR) and associated 95% CIs, which were stratified by study, were calculated post hoc using exact methods with StatXact Ò (Cytel, Cambridge, MA, USA). The IRR was defined as the rate of the event in the dapagliflozin group divided by the rate in the placebo group. Thus, an IRR upper 95% CI of \1 (1 being the null value)
would indicate that dapagliflozin was associated with a lower incidence of marked abnormalities of serum potassium than placebo. Conversely, an IRR lower 95% CI of [1 would indicate that dapagliflozin was associated with a higher incidence of marked abnormalities of serum potassium than placebo. No statistical hypothesis testing was conducted and no p values were calculated. All analyses were performed using all available data regardless of the use of rescue therapy. Mean eGFR was determined using the Modification of Diet in Renal Disease formula [33] .
RESULTS
Patients
Mean baseline demographic characteristics were well balanced between the dapagliflozin and placebo groups in the pooled population ( Patients in the dedicated moderate renal impairment study [30] were older than the pooled population (mean age: dapagliflozin 10 mg, 68 years and placebo, 67 years; vs. 58. 4 and 58.9 years in the pooled population, respectively) and had a longer duration of T2DM (mean duration: dapagliflozin 10 mg, 18.2 years and placebo, 15.7; vs. 8.9 and 8.8 years in the pooled population, respectively; Table 1 ).
Mean Change in Potassium from Baseline up to Week 24
No clinically relevant mean change from baseline in serum potassium was noted up to (Fig. 3) . The IRR upper 95% CI for serum potassium C5.5 mmol/L up to 24 weeks was below 1 for dapagliflozin 10 mg versus placebo for patients on potassium-sparing diuretics and for patients with an eGFR of C30 to \60 mL/min/1.73 m 2 on ACE inhibitors or ARBs (Fig. 3) . In the 52 week moderate renal impairment study [30] , the incidence of serum potassium C5.5 mmol/L was 20.2% with dapagliflozin 10 mg and 26.5% with placebo [IRR 0.69 (95% CI 0.34, 1.35); Fig. 3 ], with fewer patients treated with dapagliflozin discontinuing due to hyperkalemia (4.7% vs. 9.5%, respectively).
Likewise, when the higher serum potassium cut-off point of C6.0 mmol/L was used, the (52.6%), respectively; Fig. 4 ].
Marked Abnormalities of Serum Potassium ‡5.5 mmol/L Reported as Adverse Events
Very few marked abnormalities of increased potassium were reported by the individual study investigators as clinical AEs: 7 (0.3%) in the dapagliflozin 10 mg group versus 0 in the placebo group. One SAE of hyperkalemia (serum potassium of 6.4 mmol/L on day 169 of treatment) was reported in the dapagliflozin b Fig. 2 Mean change from baseline in serum potassium levels in patients at increased risk of hyperkalemia. Patients receiving a ACE inhibitors or ARBs and b potassium-sparing diuretics in the pooled population (study duration B24 weeks); c patients with moderate renal impairment [30] (study duration 52 weeks). Asterisks number of treated patients with non-missing values at baseline and at that study week. ACE angiotensin-converting enzyme, ARBs angiotensin receptor blockers, BL baseline, CI confidence interval, DAPA dapagliflozin, SD standard deviation Fig. 3 Incidence rate ratio of marked abnormalities of serum potassium C5.5 mmol/L. Asterisks short-term pooled data up to 24 weeks; dagger moderate renal impairment study (52 weeks) [30] . ACEi angiotensin-converting enzyme inhibitors, ARBs angiotensin receptor blockers, CI confidence interval, DAPA dapagliflozin, eGFR estimated glomerular filtration rate, IRR incidence rate ratio 10 mg group. This patient had a history of hyperkalemia and hypertension and was treated with perindopril, which was stopped on day 175. His re-test potassium measurement was 6.1 mmol/L on day 176 and on day 178 this had decreased further to 4.5 mmol/L, at which point the SAE was considered resolved.
Dapagliflozin dosing was not interrupted during this time.
All other AEs of hyperkalemia reported for patients in the dapagliflozin 10 mg group were reported as mild or moderate and had resolved by the next laboratory measurement (7 to 25 days later). No other patients had an AE that required treatment and no patients discontinued due to an AE of hyperkalemia. There were no reports of a serum potassium level of B2.5 mmol/L in the pooled population. Episodes of mild hypokalemia (serum potassium B3.5 mmol/L) in the pooled population were slightly more frequent with dapagliflozin than with placebo. As expected, these episodes were more common in patients receiving loop diuretics or thiazide diuretics both in patients taking dapagliflozin and placebo, with no relevant difference between the groups. Few AEs of hypokalemia were reported in either group (0.4% with dapagliflozin vs. 0.2% with placebo), and did not lead to discontinuation. There were no A trend towards increased hypokalemia risk could be consistent with dapagliflozin's mild diuretic effect [35] ; however, a lack of any difference between the groups when used with typical diuretics is both reassuring and somewhat unexpected. Renal potassium excretion is a complex process that is primarily determined by the serum aldosterone concentration and driven by the sodium concentration in the distal nephron [31, 36] . Due to the co-transportation of sodium and glucose, transient increases in urinary sodium excretion are seen for a few days upon initiation of dapagliflozin, after which levels tend to normalize [23] . Thus, unlike typical diuretics, long-term treatment with dapagliflozin should not affect sodium delivery to the distal nephron. However, it should be acknowledged that in a previous small exploratory study [35] , dapagliflozin treatment increased median plasma renin activity relative to placebo, to approximately a quarter of the hydrochlorothiazide 25 mg effect, and increased median serum aldosterone activity to a similar extent as hydrochlorothiazide. A potential trend for hypokalemia does not seem to be explained by dapagliflozin's mechanism of action, which is not reported to promote kaliuresis [34] , neither is it consistent across the SGLT2 inhibitor class, as the SGLT2 inhibitor canagliflozin has been associated with an increased risk of hyperkalemia.
Hyperkalemia risk with canagliflozin was greater in patients with moderate renal impairment or receiving ACE inhibitors, ARBs or potassium-sparing diuretics [22] , and was more pronounced with the canagliflozin 300 mg dose than the 100 mg dose [37] .
Hyperkalemia risk is greater in patients with diabetes, which may be partly attributed to hyperosmolarity caused by hyperglycemia, resulting in a shift in potassium out of cells [38] . Impaired elimination of potassium can also increase the risk of hyperkalemia [31, 36] , particularly in patients with reduced renal function or those treated with ACE inhibitors, ARBs or potassium-sparing diuretics [36] .
Monitoring potassium levels is an important consideration in patients with diabetes, particularly as these patients often have hypertension and may be treated with ACE inhibitors, ARBs and/or potassium-sparing diuretics, making them more susceptible to hyperkalemia [13, 14] . Likewise, potassium monitoring may be important in patients with renal impairment [12] , who are also considered to be at high risk of hyperkalemia [9] . Clinicians should balance the opposing risks of avoiding hyperkalemia and causing hypokalemia, or vice versa. For example, potassium-sparing diuretics have been shown to prevent diuretic-induced hypokalemia but are associated with an increased risk of hyperkalemia [39] . Furthermore, combinations of drugs with an associated risk of hyperkalemia (e.g., ACE inhibitor, ARBs, potassium-sparing diuretics [15] [16] [17] ) or hypokalemia (e.g., thiazides or loop diuretics [18] ) may rapidly precipitate serious serum electrolyte abnormalities.
Therefore, knowledge of the presence or absence of an effect on potassium homeostasis with antidiabetic drugs is important. Previous studies indicate that dapagliflozin does not affect potassium levels when taken in combination with ACE inhibitors, ARBs, thiazides or loop diuretics [40] [41] [42] .
A limitation of this analysis was the low number of patients in some of the subgroups (i.e., patients on potassium-sparing diuretics or with low eGFR), restricting the reliability of the assessment of risk for the AEs or marked abnormalities in these patients.
CONCLUSIONS
Dapagliflozin does not appear to increase serum potassium levels in patients with T2DM, including patients at a higher risk of hyperkalemia, such as those with moderate renal impairment or treated with ACE inhibitors, ARBs or potassium-sparing diuretics. Furthermore, although there were more episodes of hypokalemia overall in the dapagliflozin group, dapagliflozin was not associated with an increased risk of hypokalemia in any of the patient categories associated with increased hypokalemia risk. 
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